QLI (QLI) Stock Analysis

QLI (QLI) Healthcare & Pipeline Overview

Qilian International Holding Group Limited researches, develops, and produces active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD) in China. The company also manufactures and distributes fertilizers and sausage casings, positioning itself as a diversified player in the healthcare and agricultural sectors.

What Is the Investment Thesis for QLI?

Qilian International Holding Group Limited presents a complex investment thesis. The company's focus on APIs and TCMDs aligns with growing demand for both modern and traditional medicines. However, the company's negative profit margin of -16.7% raises concerns about its operational efficiency and cost management. The company's diversification into fertilizers and sausage casings adds complexity to its business model. The beta of 1.41 indicates higher volatility compared to the market. Investors should carefully evaluate the company's ability to improve profitability, manage its diverse operations, and navigate the regulatory landscape for pharmaceuticals and agricultural products in China.

Based on FMP financials and quantitative analysis

QLI Key Highlights

Market Cap of $38.7M reflects its small size within the pharmaceutical industry.

• Negative Profit Margin of -16.7% indicates operational inefficiencies or high costs relative to revenue.
• Gross Margin of 1.3% suggests limited pricing power or high cost of goods sold.
• Beta of 1.41 indicates higher volatility compared to the broader market.
• No Dividend Yield reflects a lack of current income for investors.

Who Are QLI's Competitors?

QLI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are QLI's Key Strengths?

Diversified product portfolio across healthcare and agriculture.

• Focus on traditional Chinese medicine derivatives (TCMD).
• Established presence in the Chinese market.
• Proprietary formulations for certain products.

What Are QLI's Weaknesses?

Negative profit margin.

• Limited brand recognition outside of China.
• Reliance on a small number of key products.
• Small market capitalization.

What Could Drive QLI Stock Higher?

Potential regulatory approvals for new pharmaceutical products.

• Expansion of sales and distribution network within China.
• Development of new traditional Chinese medicine derivatives (TCMD).

What Are the Key Risks for QLI?

Negative return on equity (-16.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Increased competition from generic drug manufacturers.
• Stringent regulatory requirements for pharmaceutical production.
• Fluctuations in raw material prices.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for QLI?

• Expansion of API Production: Qilian International can capitalize on the growing demand for APIs in China and globally. The global API market is projected to reach $292.7 billion by 2028, growing at a CAGR of 6.1%. By increasing its API production capacity and diversifying its API portfolio, Qilian International can capture a larger share of this market. This expansion could involve strategic partnerships with pharmaceutical companies or investments in advanced manufacturing technologies.
• Increased TCMD Product Development: The market for traditional Chinese medicine derivatives (TCMD) is expanding, driven by consumer interest in natural and holistic healthcare solutions. Qilian International can invest in research and development to create new TCMD products and formulations. This includes conducting clinical trials to validate the efficacy of its TCMD products and obtaining regulatory approvals for their sale in China and international markets. The timeline for new product development can range from 2-5 years.
• Geographic Expansion within China: Qilian International can expand its sales and distribution network to reach new geographic markets within China. This can involve establishing partnerships with regional distributors, opening new sales offices, and participating in trade shows and industry events. The company can focus on regions with high demand for its licorice products, oxytetracycline tablets, and TCMD products. Geographic expansion can increase revenue and reduce reliance on its existing customer base.
• Strategic Partnerships in Agriculture: The company's diversification into fertilizers provides an opportunity to capitalize on the growing demand for organic and compound fertilizers in China's agricultural sector. Qilian International can form strategic partnerships with agricultural companies, farmers' cooperatives, and government agencies to promote the use of its Xiongguan fertilizers. This includes conducting field trials to demonstrate the benefits of its fertilizers and providing technical support to farmers. These partnerships can increase sales and market share in the agricultural sector.
• Product Diversification in Healthcare: Qilian International can diversify its healthcare product portfolio by developing and marketing new pharmaceutical products and medical devices. This can involve licensing or acquiring new technologies, conducting clinical trials, and obtaining regulatory approvals. The company can focus on therapeutic areas with unmet medical needs, such as cardiovascular diseases, diabetes, and infectious diseases. Product diversification can reduce reliance on its existing product lines and increase revenue growth.

What Are QLI's Competitive Advantages?

• Proprietary formulations for traditional Chinese medicine derivatives (TCMD).
• Established relationships with pharmaceutical companies and distributors in China.
• Diversified product portfolio across healthcare and agriculture.
• Access to local resources for licorice and other raw materials.

What Does QLI Do?

Qilian International Holding Group Limited, incorporated in 2019 and based in Jiuquan, China, operates within the healthcare sector, focusing on the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD). The company's product portfolio includes licorice products such as Gan Di Xin (an antitussive and expectorant), Qilian Shan Licorice Extract (used in traditional licorice tablets), and Qilian Shan licorice liquid extract (used in compound licorice oral solutions). Additionally, Qilian International offers Qilian Shan oxytetracycline tablets and APIs, used to prevent and treat diseases in animals and humans. The company also produces TCMD products like Ahan antibacterial paste for skin diseases, and heparin products for cardiovascular and cerebrovascular medications. Beyond pharmaceuticals, Qilian International manufactures Zhu Xiaochang sausage casings and Xiongguan organic and organic-inorganic compound fertilizers, diversifying its revenue streams across both healthcare and agriculture. This diversification strategy aims to leverage traditional Chinese medicine and agricultural resources in the region.

What Products and Services Does QLI Offer?

• Researches and develops active pharmaceutical ingredients (APIs).
• Produces traditional Chinese medicine derivatives (TCMD).
• Manufactures licorice products for pharmaceutical applications.
• Offers oxytetracycline tablets and APIs for animal and human health.
• Produces Ahan antibacterial paste for skin diseases.
• Manufactures heparin products for cardiovascular and cerebrovascular treatments.
• Produces Zhu Xiaochang sausage casings for culinary use.
• Manufactures Xiongguan organic and organic-inorganic compound fertilizers.

How Does QLI Make Money?

• Develops and manufactures APIs and TCMDs.
• Sells pharmaceutical products, including licorice extracts and oxytetracycline.
• Manufactures and sells agricultural fertilizers.
• Generates revenue through the sale of sausage casings.

What Industry Does QLI Operate In?

Qilian International Holding Group Limited operates in the specialty and generic drug manufacturing industry, which is characterized by intense competition and pricing pressures. The Chinese pharmaceutical market is experiencing growth, driven by increasing healthcare expenditure and an aging population. The company's focus on traditional Chinese medicine derivatives (TCMD) positions it within a segment that benefits from cultural preferences and government support for traditional medicine. However, the company also faces competition from established generic drug manufacturers and evolving regulatory standards for pharmaceutical production and quality control.

Who Are QLI's Key Customers?

• Pharmaceutical companies that use its APIs and licorice extracts.
• Medical preparation companies that use its licorice liquid extract.
• Farmers who use its organic and compound fertilizers.
• Consumers who purchase its oxytetracycline tablets and Ahan antibacterial paste.
• Food processing companies that use its sausage casings.

Company Profile

QLI operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Jiuquan, CN. The company is led by CEO Chen Xin. QLI has traded publicly since 2021.

QLI's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.42 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for QLI stands at -16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.

QLI Valuation & Market Position

With a $38.7M market cap, QLI sits in the micro-cap segment of the market.

QLI Financials

QLI Latest News

QLI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources